This Week In Cannabis: Big Earnings Reports, Ice Cube's New Brand, Trump's Mixed Signals, Germany's Import Boom And Much More
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 02 2025
0mins
Should l Buy CRON?
Source: Benzinga
Market Developments: This week saw significant moves in the cannabis industry, including LFTD Partners entering the Illinois market, Trulieve launching a THC-infused beverage line, and Ice Cube unveiling his cannabis brand Fryday Kush. Additionally, Germany's cannabis imports surged, while New Jersey and Ohio faced legislative challenges regarding cannabis laws.
Regulatory Changes and Social Initiatives: New York is implementing a $5 million grant program for social equity cannabis retailers, while New Jersey proposes a tax hike on cannabis products. Meanwhile, WWE has reportedly removed marijuana from its banned substances list, reflecting changing attitudes towards cannabis in sports.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CRON?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CRON
Wall Street analysts forecast CRON stock price to rise
2 Analyst Rating
1 Buy
1 Hold
0 Sell
Moderate Buy
Current: 2.510
Low
2.30
Averages
2.72
High
3.14
Current: 2.510
Low
2.30
Averages
2.72
High
3.14
About CRON
Cronos Group Inc. is a global cannabinoid company engaged in building disruptive intellectual property by advancing cannabis research, technology and product development. The Company’s diverse international brand portfolio includes Spinach, PEACE NATURALS and Lord Jones. Spinach is a mainstream adult-use cannabis brand with a portfolio that includes cannabinoid products in a wide range of formats, including dried flower, pre-rolls, vaporizers, edibles and tinctures. Lord Jones is a premium adult-use cannabis brand. The Lord Jones brand portfolio includes cannabis products in the pre-roll, vaporizer and edible categories. Lord Jones Ice Water Hash Fusions pre-rolls feature flower and terpene-rich ice water hash and are fitted with a branded ceramic tip. PEACE NATURALS is a global medical brand engaged in producing cannabis products. The Company distributes products under the PEACE NATURALS brand for the Canadian market and the Israeli, German, and United Kingdom medical markets.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Altria Faces Challenges in Tobacco Market
- Stock Performance Review: While Altria has historically achieved an annual return of 20%, its performance over the past decade has been lackluster due to declining smoking rates in the U.S., highlighting the vulnerability of its core business.
- Diversification Failures: Altria's investments in Cronos Group and Juul Labs have resulted in billions in losses, and its recent acquisition of NJOY faced a ban from the U.S. International Trade Commission due to patent infringement, exacerbating financial pressures.
- New Product Sales Growth: Despite the decline in its core business, Altria's On! oral nicotine pouches saw an 11% increase in sales to 177.8 million cans over the past year, but a drop in market share indicates competitive pressures, particularly from Philip Morris's Zyn.
- Future Earnings Outlook: Altria projects earnings per share growth of 2.5% to 5.5%, reaching $5.56 to $5.72 in 2026, and with a 6.3% dividend yield, it still presents some investment appeal despite the risks associated with its declining core business.
See More
Altria's Diversification Efforts Falter
- Core Business Decline: Altria has managed profit growth by raising cigarette prices, yet its 2025 revenue after excise taxes fell 1.5% to $20.1 billion, indicating a persistent decline in its core business and significant risks for future growth.
- New Product Market Competition: Altria's On! oral nicotine pouches saw an 11% shipment increase to 177.8 million cans over the past year, but a decline in market share in Q4 due to Zyn's promotions suggests limited market acceptance for new products.
- Shareholder Returns and Risks: Despite a roughly 50% stock price increase over the past two years, Altria's 2026 earnings per share target of $5.56 to $5.72, combined with a 6.3% dividend yield, highlights the challenges and uncertainties the company faces during its transition.
- Uncertain Industry Outlook: With smoking rates among young Americans continuing to decline, Altria's cigarette sales are almost certain to keep falling, and if the company cannot replace lost profits with new products, its long-term stock price will face downward pressure.
See More
Cronos Group Reports Record Growth in 2025 Earnings Call
- Significant Revenue Growth: Cronos Group reported a consolidated net revenue of $44.5 million for Q4 2025, reflecting a 47% year-over-year increase driven by strong cannabis flower sales in Israel and Canada, underscoring the continued strength of its core business.
- Market Leadership Reinforced: The Spinach brand emerged as the second-largest vape brand in Canada and achieved the top market share in vape cartridges, further solidifying the company's leadership position in the rapidly growing consumer goods market.
- Strategic Acquisition Plans: The company announced a definitive agreement to acquire CanAdelaar, the largest operator in the Netherlands' legal adult-use cannabis program, for €57.5 million (approximately $67.5 million), with closing expected in H1 2026, which will provide robust support for the company's expansion into the European market.
- Strong Financial Position: Cronos Group maintains the strongest balance sheet in the industry with no debt and $832 million in cash and short-term investments, demonstrating the company's financial flexibility for future expansions and acquisitions.
See More
Cronos Reports Q4 Revenue Beat Despite Net Loss
- Significant Revenue Growth: Cronos reported $44.5 million in revenue for Q4 2025, reflecting approximately 47% year-over-year growth, exceeding market expectations by $5.8 million, primarily driven by improved flower sales in multiple countries, including Israel.
- Gross Profit Increase: The company's gross profit rose nearly 50% year-over-year to $16.2 million, indicating enhanced sales volumes and average selling prices, although overall performance was impacted by foreign currency transaction losses.
- Net Loss Reported: Despite revenue growth, Cronos swung to a net loss of $0.5 million from a net income of $43.9 million in the prior-year period, highlighting the significant impact of foreign exchange losses on the company's financials.
- Annual Financial Overview: For the full year, Cronos posted a net loss of $9.4 million on $146.6 million in revenue, indicating approximately 25% year-over-year growth, while cash and cash equivalents fell about 8% year-over-year to $791.8 million, reflecting financial pressures amid market expansion efforts.
See More
Cronos Group Q4 Earnings Beat Expectations with Strong Revenue Growth
- Earnings Highlights: Cronos Group reported a Q4 GAAP EPS of $0.00, missing expectations by $0.02; however, revenue reached $44.53 million, reflecting a 47% year-over-year increase and exceeding market expectations by $5.78 million, indicating strong revenue growth.
- Adjusted EBITDA Improvement: The adjusted EBITDA for Q4 was $0.5 million, improving by $7.7 million from Q4 2024, primarily driven by higher adjusted gross profit, showcasing significant progress in cost control and profitability.
- Geographic Expansion Strategy: Supported by a strong balance sheet, Cronos Group is actively pursuing geographic expansion to enhance market share and brand influence, particularly in the rapidly growing legal cannabis market.
- Competitive Advantage: Cronos Group boasts a standout balance sheet compared to its peers, strengthening its competitive position in the industry and providing a relatively safe investment option amid future market fluctuations.
See More
Cronos Group Reports Fourth Quarter Loss
- Quarterly Loss: Cronos Group reported a swing to a loss in the fourth quarter, indicating pressure from market competition that may undermine investor confidence.
- Stock Price Decline: The stock fell 4% in U.S. pre-market trading, reflecting negative market sentiment regarding its financial performance, which could lead to short-term capital outflows.
- Market Environment Challenges: The company faces intense industry competition and regulatory pressures, impacting its profitability and creating uncertainty around future growth prospects.
- Investor Attention: Investors should closely monitor the company's strategic adjustments and market responses to assess its long-term investment value and potential returns.
See More
Altria Faces Challenges in Tobacco Market
- Stock Performance Review: While Altria has historically achieved an annual return of 20%, its performance over the past decade has been lackluster due to declining smoking rates in the U.S., highlighting the vulnerability of its core business.
- Diversification Failures: Altria's investments in Cronos Group and Juul Labs have resulted in billions in losses, and its recent acquisition of NJOY faced a ban from the U.S. International Trade Commission due to patent infringement, exacerbating financial pressures.
- New Product Sales Growth: Despite the decline in its core business, Altria's On! oral nicotine pouches saw an 11% increase in sales to 177.8 million cans over the past year, but a drop in market share indicates competitive pressures, particularly from Philip Morris's Zyn.
- Future Earnings Outlook: Altria projects earnings per share growth of 2.5% to 5.5%, reaching $5.56 to $5.72 in 2026, and with a 6.3% dividend yield, it still presents some investment appeal despite the risks associated with its declining core business.
See More
Altria's Diversification Efforts Falter
- Core Business Decline: Altria has managed profit growth by raising cigarette prices, yet its 2025 revenue after excise taxes fell 1.5% to $20.1 billion, indicating a persistent decline in its core business and significant risks for future growth.
- New Product Market Competition: Altria's On! oral nicotine pouches saw an 11% shipment increase to 177.8 million cans over the past year, but a decline in market share in Q4 due to Zyn's promotions suggests limited market acceptance for new products.
- Shareholder Returns and Risks: Despite a roughly 50% stock price increase over the past two years, Altria's 2026 earnings per share target of $5.56 to $5.72, combined with a 6.3% dividend yield, highlights the challenges and uncertainties the company faces during its transition.
- Uncertain Industry Outlook: With smoking rates among young Americans continuing to decline, Altria's cigarette sales are almost certain to keep falling, and if the company cannot replace lost profits with new products, its long-term stock price will face downward pressure.
See More
Cronos Group Reports Record Growth in 2025 Earnings Call
- Significant Revenue Growth: Cronos Group reported a consolidated net revenue of $44.5 million for Q4 2025, reflecting a 47% year-over-year increase driven by strong cannabis flower sales in Israel and Canada, underscoring the continued strength of its core business.
- Market Leadership Reinforced: The Spinach brand emerged as the second-largest vape brand in Canada and achieved the top market share in vape cartridges, further solidifying the company's leadership position in the rapidly growing consumer goods market.
- Strategic Acquisition Plans: The company announced a definitive agreement to acquire CanAdelaar, the largest operator in the Netherlands' legal adult-use cannabis program, for €57.5 million (approximately $67.5 million), with closing expected in H1 2026, which will provide robust support for the company's expansion into the European market.
- Strong Financial Position: Cronos Group maintains the strongest balance sheet in the industry with no debt and $832 million in cash and short-term investments, demonstrating the company's financial flexibility for future expansions and acquisitions.
See More
Cronos Reports Q4 Revenue Beat Despite Net Loss
- Significant Revenue Growth: Cronos reported $44.5 million in revenue for Q4 2025, reflecting approximately 47% year-over-year growth, exceeding market expectations by $5.8 million, primarily driven by improved flower sales in multiple countries, including Israel.
- Gross Profit Increase: The company's gross profit rose nearly 50% year-over-year to $16.2 million, indicating enhanced sales volumes and average selling prices, although overall performance was impacted by foreign currency transaction losses.
- Net Loss Reported: Despite revenue growth, Cronos swung to a net loss of $0.5 million from a net income of $43.9 million in the prior-year period, highlighting the significant impact of foreign exchange losses on the company's financials.
- Annual Financial Overview: For the full year, Cronos posted a net loss of $9.4 million on $146.6 million in revenue, indicating approximately 25% year-over-year growth, while cash and cash equivalents fell about 8% year-over-year to $791.8 million, reflecting financial pressures amid market expansion efforts.
See More
Cronos Group Q4 Earnings Beat Expectations with Strong Revenue Growth
- Earnings Highlights: Cronos Group reported a Q4 GAAP EPS of $0.00, missing expectations by $0.02; however, revenue reached $44.53 million, reflecting a 47% year-over-year increase and exceeding market expectations by $5.78 million, indicating strong revenue growth.
- Adjusted EBITDA Improvement: The adjusted EBITDA for Q4 was $0.5 million, improving by $7.7 million from Q4 2024, primarily driven by higher adjusted gross profit, showcasing significant progress in cost control and profitability.
- Geographic Expansion Strategy: Supported by a strong balance sheet, Cronos Group is actively pursuing geographic expansion to enhance market share and brand influence, particularly in the rapidly growing legal cannabis market.
- Competitive Advantage: Cronos Group boasts a standout balance sheet compared to its peers, strengthening its competitive position in the industry and providing a relatively safe investment option amid future market fluctuations.
See More
Cronos Group Reports Fourth Quarter Loss
- Quarterly Loss: Cronos Group reported a swing to a loss in the fourth quarter, indicating pressure from market competition that may undermine investor confidence.
- Stock Price Decline: The stock fell 4% in U.S. pre-market trading, reflecting negative market sentiment regarding its financial performance, which could lead to short-term capital outflows.
- Market Environment Challenges: The company faces intense industry competition and regulatory pressures, impacting its profitability and creating uncertainty around future growth prospects.
- Investor Attention: Investors should closely monitor the company's strategic adjustments and market responses to assess its long-term investment value and potential returns.
See More
